Top Page
Liquidia Technologies
(NASDAQ:LQDA)
Liquidia Technologies (LQDA) vs. SPDR S&P 500 ETF (SPY)
Liquidia Technologies Business Overview & Revenue Model
Liquidia Technologies Earnings Call Summary
Liquidia Technologies Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 14.00M | 17.49M | 15.94M | 12.85M | 739.63K |
| Gross Profit | 8.12M | 14.60M | 13.08M | 9.83M | 501.92K |
| EBITDA | -115.71M | -70.05M | -34.72M | -27.91M | -55.79M |
| Net Income | -130.39M | -78.50M | -38.37M | -29.78M | -57.49M |
Balance Sheet | |||||
| Total Assets | 230.31M | 118.33M | 129.20M | 93.73M | 99.53M |
| Cash, Cash Equivalents and Short-Term Investments | 176.48M | 83.68M | 93.28M | 57.49M | 65.32M |
| Total Debt | 122.39M | 3.50M | 24.46M | 16.08M | 17.14M |
| Total Liabilities | 153.04M | 71.04M | 38.78M | 28.46M | 28.45M |
| Stockholders Equity | 77.28M | 47.29M | -350.60M | -309.58M | -275.00M |
Cash Flow | |||||
| Free Cash Flow | -98.37M | -42.85M | -29.18M | -34.14M | -54.90M |
| Operating Cash Flow | -93.42M | -41.56M | -28.59M | -34.04M | -54.14M |
| Investing Cash Flow | -8.44M | -11.29M | -587.00K | -107.22K | 247.91K |
| Financing Cash Flow | 194.66M | 43.25M | 64.96M | 26.32M | 63.42M |
Liquidia Technologies Technical Analysis
Liquidia Technologies Risk Analysis
Liquidia Technologies Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $1.23B | 32.84 | 11.23% | ― | 29.20% | ― | |
67 Neutral | $1.27B | 2.96 | 30.06% | ― | 25.92% | ― | |
64 Neutral | $1.05B | ― | -36.26% | ― | 127.33% | 21.31% | |
60 Neutral | $1.52B | ― | -188.03% | ― | -11.42% | 0.26% | |
52 Neutral | $1.54B | ― | -23.20% | ― | 24.49% | 5.14% | |
52 Neutral | $7.61B | 0.10 | -63.03% | 2.08% | 16.34% | 0.32% | |
51 Neutral | $1.90B | ― | -57.19% | ― | -0.33% | -3.59% |
Liquidia Technologies Corporate Events
On July 1, 2025, Liquidia Corporation appointed Dana Boyle as the Chief Accounting Officer. Previously serving as the Senior Vice President, Finance and Controller since January 2021, Boyle brings extensive experience from her roles at Aerami Therapeutics and Aralez Pharmaceuticals. Her appointment includes a salary of $425,000, a discretionary bonus, and restricted stock units vesting over four years. Boyle’s severance benefits are outlined under the company’s executive severance plan, ensuring financial security in the event of termination.
The most recent analyst rating on (LQDA) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Liquidia Technologies stock, see the LQDA Stock Forecast page.
On June 23, 2025, Liquidia Corporation announced receiving an additional $50 million in funding under its agreement with Healthcare Royalty Partners IV, following the first commercial sale of YUTREPIA after the U.S. District Court denied an injunction request by United Therapeutics. This funding will support Liquidia’s launch execution, clinical pipeline advancement, and manufacturing expansion, reinforcing its financial position and ability to achieve profitability. The company has received $175 million of the potential $200 million funding, with an additional $25 million available upon achieving certain sales milestones.
The most recent analyst rating on (LQDA) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Liquidia Technologies stock, see the LQDA Stock Forecast page.
On June 16, 2025, Liquidia Technologies entered into a lease agreement for a new manufacturing facility in Morrisville, North Carolina, with King Combs LLC. The lease, which spans approximately 70,131 square feet, will commence on June 16, 2025, and expire on November 1, 2036, with options for extension. The agreement includes a monthly base rent starting at $260,069.13 from May 1, 2026, with a 3% annual increase, and a six-month rent abatement period. This move is expected to enhance Liquidia’s manufacturing capabilities and potentially expand its operational footprint.
The most recent analyst rating on (LQDA) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Liquidia Technologies stock, see the LQDA Stock Forecast page.
On June 17, 2025, Liquidia Corporation held its annual meeting of stockholders where key decisions were made, including the election of three Class I directors, the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2025, and the approval of executive compensation. The meeting saw participation from holders of 67,560,757 shares, constituting a quorum, and all proposals were passed with significant support.
The most recent analyst rating on (LQDA) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Liquidia Technologies stock, see the LQDA Stock Forecast page.
On June 2, 2025, Liquidia Corporation announced that the U.S. District Court for the Middle District of North Carolina denied United Therapeutics Corporation’s motion for a preliminary injunction and temporary restraining order against Liquidia. This decision, made on May 30, 2025, allows Liquidia to proceed with the commercialization of YUTREPIA™ (treprostinil) inhalation powder, which was approved by the FDA on May 23, 2025, for treating PAH and PH-ILD. The court’s ruling clears the way for Liquidia to make its first commercial shipment of YUTREPIA, marking a significant milestone in the company’s operations and positioning it to offer a new therapeutic alternative in the market.
The most recent analyst rating on (LQDA) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Liquidia Technologies stock, see the LQDA Stock Forecast page.
On May 23, 2025, Liquidia Corporation announced that its product YUTREPIA received final FDA approval for treating PAH and PH-ILD. The approval follows the expiration of exclusivity rights held by United Therapeutics, which had delayed YUTREPIA’s approval. Despite this milestone, ongoing and potential litigation could impact the product’s commercialization. Liquidia plans to begin marketing YUTREPIA immediately, emphasizing its ease of use and effectiveness demonstrated in clinical trials. The approval is expected to provide a new treatment option for patients, although legal challenges from United Therapeutics may pose obstacles.
The most recent analyst rating on (LQDA) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Liquidia Technologies stock, see the LQDA Stock Forecast page.
On May 12, 2025, Liquidia Corporation announced that United Therapeutics Corporation filed a complaint against them on May 9, 2025, in the U.S. District Court for the Middle District of North Carolina. The complaint alleges infringement of U.S. Patent No. 11,357,782 and seeks to prevent Liquidia from commercializing YUTREPIA™ if it receives FDA approval. Despite the litigation, the FDA’s ability to take final action on the New Drug Application for YUTREPIA by the PDUFA goal date of May 24, 2025, remains unaffected. Liquidia’s CEO, Dr. Roger Jeffs, expressed determination to defend patient access to alternative therapies, highlighting past successes in invalidating similar patent claims.
Liquidia Corporation has voluntarily corrected immaterial accounting errors related to amendments in its revenue interest financing agreement with HealthCare Royalty Partners. These errors, identified in March 2025, were deemed not material to previous financial statements but have been revised to reflect modifications rather than extinguishments. The revisions do not impact the company’s internal controls or management’s assessment of financial condition, and the company’s independent auditor, PricewaterhouseCoopers LLP, has updated its audit report accordingly.